Total Payments
$16,154
2024 Payments
$3,381
Companies
19
Transactions
37
Medicare Patients
466
Medicare Billing
$89,568
Payment Breakdown by Category
Consulting$8,340 (51.6%)
Research$3,020 (18.7%)
Other$2,106 (13.0%)
Food & Beverage$1,763 (10.9%)
Travel$825.99 (5.1%)
Education$99.00 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,340 | 5 | 51.6% |
| Unspecified | $3,020 | 3 | 18.7% |
| Honoraria | $2,000 | 1 | 12.4% |
| Food and Beverage | $1,763 | 22 | 10.9% |
| Travel and Lodging | $825.99 | 4 | 5.1% |
| Grant | $106.00 | 1 | 0.7% |
| Education | $99.00 | 1 | 0.6% |
Payments by Type
General
$13,134
34 transactions
Research
$3,020
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $4,252 | 8 | $0 (2020) |
| F. Hoffmann-La Roche AG | $3,020 | 3 | $0 (2024) |
| ADC Therapeutics America, Inc. | $2,000 | 1 | $0 (2021) |
| BeiGene USA, Inc. | $1,736 | 2 | $0 (2021) |
| MorphoSys, US Inc. | $1,440 | 1 | $0 (2021) |
| Janssen Biotech, Inc. | $1,021 | 2 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $855.41 | 2 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $288.00 | 2 | $0 (2017) |
| Genmab U.S., Inc. | $282.97 | 3 | $0 (2024) |
| Genentech USA, Inc. | $196.63 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,381 | 7 | F. Hoffmann-La Roche AG ($3,020) |
| 2023 | $112.67 | 1 | Genmab U.S., Inc. ($112.67) |
| 2022 | $1,010 | 1 | Janssen Biotech, Inc. ($1,010) |
| 2021 | $5,176 | 4 | ADC Therapeutics America, Inc. ($2,000) |
| 2020 | $138.91 | 2 | Astellas Pharma US Inc ($99.00) |
| 2019 | $4,618 | 12 | Gilead Sciences, Inc. ($4,212) |
| 2018 | $1,305 | 7 | Bayer HealthCare Pharmaceuticals Inc. ($855.41) |
| 2017 | $413.00 | 3 | E.R. Squibb & Sons, L.L.C. ($288.00) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,079.32 | Research |
| Study: Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-cell Lymphoma Using Real-World Data | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $268.78 | Research |
| Study: Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-cell Lymphoma Using Real-World Data | ||||||
| 12/09/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $96.67 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $71.63 | General |
| 11/14/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $73.63 | General |
| Category: Oncology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,671.85 | Research |
| Study: Polarix | ||||||
| 07/18/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $118.99 | General |
| Category: CELLT | ||||||
| 12/11/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $112.67 | General |
| Category: Oncology | ||||||
| 03/15/2022 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $1,010.00 | General |
| Category: Oncology | ||||||
| 12/16/2021 | ADC Therapeutics America, Inc. | — | Honoraria | Cash or cash equivalent | $2,000.00 | General |
| 12/02/2021 | MorphoSys, US Inc. | MONJUVI (Drug) | Consulting Fee | Cash or cash equivalent | $1,440.00 | General |
| Category: Oncology | ||||||
| 07/06/2021 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $85.71 | General |
| Category: Oncology | ||||||
| 01/07/2021 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 02/14/2020 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.00 | General |
| 01/23/2020 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $39.91 | General |
| 12/20/2019 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,440.00 | General |
| 12/08/2019 | Celgene Corporation | JCAR017 (Drug) | Food and Beverage | In-kind items and services | $49.32 | General |
| 11/09/2019 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $336.73 | General |
| 11/09/2019 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $217.26 | General |
| 11/09/2019 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $90.00 | General |
| 11/09/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $65.00 | General |
| 11/09/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $36.83 | General |
| 11/09/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.96 | General |
| 09/05/2019 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $114.30 | General |
| Category: Hematology / Oncology | ||||||
| 08/13/2019 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Hematology/Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Polarix | F. Hoffmann-La Roche AG | $1,672 | 1 |
| Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-cell Lymphoma Using Real-World Data | F. Hoffmann-La Roche AG | $1,348 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 123 | 272 | $37,579 | $24,878 |
| 2022 | 2 | 105 | 230 | $36,202 | $22,445 |
| 2021 | 3 | 110 | 246 | $39,673 | $22,665 |
| 2020 | 4 | 128 | 272 | $34,178 | $19,581 |
Total Patients
466
Total Services
1,020
Medicare Billing
$89,568
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 66 | 183 | $29,457 | $19,291 | 65.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 44 | 73 | $7,580 | $5,223 | 68.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 13 | 16 | $542.00 | $363.00 | 67.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 67 | 176 | $30,442 | $18,654 | 61.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 38 | 54 | $5,760 | $3,791 | 65.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 56 | 136 | $21,797 | $14,346 | 65.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 42 | 63 | $6,831 | $4,403 | 64.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 47 | $11,045 | $3,916 | 35.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 57 | 176 | $22,628 | $14,397 | 63.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 36 | 53 | $4,953 | $3,147 | 63.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 22 | 25 | $5,409 | $1,546 | 28.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 13 | 18 | $1,188 | $490.88 | 41.3% |
About Dr. Bei Hu, MD
Dr. Bei Hu, MD is a Hematology & Oncology healthcare provider based in Charlotte, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/12/2011. The National Provider Identifier (NPI) number assigned to this provider is 1548550494.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bei Hu, MD has received a total of $16,154 in payments from pharmaceutical and medical device companies, with $3,381 received in 2024. These payments were reported across 37 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($8,340).
As a Medicare-enrolled provider, Hu has provided services to 466 Medicare beneficiaries, totaling 1,020 services with total Medicare billing of $89,568. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology, Hematology
- Location Charlotte, NC
- Active Since 04/12/2011
- Last Updated 09/25/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1548550494
Products in Payments
- BRUKINSA (Drug) $1,736
- MONJUVI (Drug) $1,440
- IMBRUVICA (Drug) $1,021
- Aliqopa (Drug) $855.41
- Epkinly (Drug) $282.97
- Yescarta (Drug) $147.84
- Folotyn (Drug) $146.03
- GAZYVA (Biological) $125.00
- JAKAFI (Drug) $124.99
- Revlimid (Drug) $114.30
- Venclexta (Drug) $106.57
- CALQUENCE (Drug) $103.90
- Blincyto (Biological) $101.39
- CELLEXXTS PHOTOPHERESIS SYSTEM (Device) $69.35
- JCAR017 (Drug) $49.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Charlotte
Dr. Alan Zausner Skarbnik, Md, MD
Hematology & Oncology — Payments: $1.3M
Hematology & Oncology $1.3M
Shebli Atrash, Md, MD
Hematology & Oncology — Payments: $718,073
Hematology & Oncology $718,073
Ruben Mesa, Md, MD
Hematology & Oncology — Payments: $474,884
Hematology & Oncology $474,884
Nasfat Shehadeh, Md, MD
Hematology & Oncology — Payments: $78,512
Hematology & Oncology $78,512
Justin Favaro, Md, MD
Hematology & Oncology — Payments: $35,791
Hematology & Oncology $35,791
Brittany Ragon, Md, MD
Hematology & Oncology — Payments: $13,167
Hematology & Oncology $13,167